Compare GSK plc (GSK) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Gartner Inc — how do they compare? GSK plc trades at $46.87 (market cap $95.18B), while Gartner Inc trades at $195.41 (market cap $11.73B). The key difference: GSK plc is far larger — about 8.1× Gartner Inc's market cap, and GSK plc pays a 3.86% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Gartner Inc for 64 Days on average.
| GSK | IT | |
|---|---|---|
Market Cap | $95.18B | $11.73B |
Volume | 5,852,596 | 736,899 |
Sector | Health | Technology |
52-Week High | $61.18 | $258.17 |
52-Week Low | $43.24 | $125.68 |
Typical Hold Time | 93 Days | 64 Days |
Enterprise Value | $115.25B | $13.48B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Gartner (IT) trades at $185.77, up 0.46% today, showing strong technical momentum with a bullish moving average signal. The company maintains robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and impressive profitability metrics including 69.63% gross margin and 113.58% ROE. Recent news highlights Gartner's leadership position in AI advisory services and strong industry recognition.
While valuation appears reasonable with P/E of 16.71, the stock faces headwinds from negative cash flow trends and a high P/B ratio of 160.06. Analyst consensus is mixed with 27.78% buy ratings but a consensus price target below current levels at $174.63, suggesting limited near-term upside potential despite strong business fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
